Prioritization of HCV treatment in the direct-acting antiviral era: An evaluation.
暂无分享,去创建一个
G. Dore | P. Vickerman | M. Hickman | G. Foster | N. Martin | J. Grebely | J. Cairns | T. Martin | D. Goldberg | M. Ramsay | Sharon Hutchinson | A. Miners
[1] R. Kamel. AASLD 2016 Recommendations for Testing, Managing, and Treating Hepatitis C , 2017 .
[2] Karl Claxton,et al. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.
[3] J. Ward,et al. Cost‐effectiveness of hepatitis C treatment for patients in early stages of liver disease , 2015, Hepatology.
[4] G. Dore,et al. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] Brian L. Pearlman,et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.
[6] H. Razavi,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.
[7] D. De Angelis,et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact , 2014, Journal of viral hepatitis.
[8] Ross J. Harris,et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. , 2014, Journal of hepatology.
[9] M. Abdel-hamid,et al. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. , 2014, The Lancet. Global health.
[10] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[11] M. Buti,et al. Strategies to manage hepatitis C virus (HCV) disease burden , 2014, Journal of viral hepatitis.
[12] O. Weiland,et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.
[13] R. Chung,et al. O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION , 2014 .
[14] D. Jensen,et al. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? , 2014, Hepatology.
[15] P. Vickerman,et al. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] P. Vickerman,et al. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons , 2013, BMJ Open.
[17] M. Hellard,et al. Assessing the cost‐effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia , 2013, Journal of gastroenterology and hepatology.
[18] Bryce D. Smith,et al. Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma , 2013, Annals of Internal Medicine.
[19] M. Manns,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.
[20] P. Vickerman,et al. P53 The cost-effectiveness of HCV antiviral treatment for injecting drug user populations , 2011, Gut.
[21] P. Vickerman,et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. , 2011, Journal of hepatology.
[22] J. Shepherd,et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. , 2011, Health technology assessment.
[23] Rosie P Cornish,et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database , 2010, BMJ : British Medical Journal.
[24] D. De Angelis,et al. An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales , 2009, Statistical methods in medical research.
[25] D. De Angelis,et al. Estimating the prevalence of ex-injecting drug use in the population , 2009, Statistical methods in medical research.
[26] A. Chiesa,et al. Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study , 2009, The American Journal of Gastroenterology.
[27] W. Edmunds,et al. The cost‐effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost‐utility analysis , 2008, Journal of viral hepatitis.
[28] N. Waugh,et al. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C : a systematic review and economic evaluation , 2007 .
[29] U. Siebert,et al. Case finding for hepatitis C in primary care: a cost utility analysis. , 2006, Family practice.
[30] Jennifer A. Roberts,et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. , 2006, Health technology assessment.
[31] R. Stohler,et al. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis , 2006, The Lancet.
[32] Colin W Shepard,et al. Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.
[33] J. D. Sellman,et al. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? , 2004, Drug and alcohol review.
[34] P. Royle,et al. Screening for Hepatitis C in injecting drug users: a cost utility analysis. , 2004, Journal of public health.
[35] J. Moatti,et al. PREVENTION COULD BE LESS COST-EFFECTIVE THAN CURE: THE CASE OF HEPATITIS C SCREENING POLICIES IN FRANCE , 2003, International Journal of Technology Assessment in Health Care.
[36] Paul Kind,et al. UK population norms for EQ-5D , 1999 .
[37] W. Rosenberg,et al. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? , 1999, Journal of medical screening.
[38] G. Práctica,et al. European Association for the Study of the Liver , 1971 .
[39] M. Postma,et al. Updated healthcare cost estimate for drug-related hepatitis C infections in the European Union , 2004 .